NovaBridge Financial Statements From 2010 to 2026

NBP Stock   3.85  0.19  5.19%   
Analyzing historical trends in various income statement and balance sheet accounts from NovaBridge Biosciences' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting NovaBridge Biosciences' valuation are summarized below:
There are currently one hundred twenty fundamental ratios for NovaBridge Biosciences that can be evaluated and compared over time across peers in the industry. Investors and active traders are advised to check NovaBridge Biosciences' last-minute fundamental performance against the performance between 2010 and 2026 to make sure the trends are evolving in the right direction. As of 01/17/2026, Market Cap is likely to drop to about 75.4 M. In addition to that, Enterprise Value is likely to drop to about 5.1 M

NovaBridge Biosciences Total Revenue

0.0

Check NovaBridge Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NovaBridge Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.6 M, Interest Expense of 87.1 K or Selling General Administrative of 432.4 M, as well as many indicators such as Price To Sales Ratio of 153, Dividend Yield of 8.0E-4 or PTB Ratio of 0.32. NovaBridge financial statements analysis is a perfect complement when working with NovaBridge Biosciences Valuation or Volatility modules.
  
Build AI portfolio with NovaBridge Stock
Check out the analysis of NovaBridge Biosciences Correlation against competitors.
To learn how to invest in NovaBridge Stock, please use our How to Invest in NovaBridge Biosciences guide.

NovaBridge Biosciences Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets232.4 M244.6 M1.9 B
Pretty Stable
Short and Long Term Debt Total3.3 M3.5 M134.9 M
Slightly volatile
Other Current Liabilities8.2 M8.7 M215 M
Slightly volatile
Total Current Liabilities7.2 M7.6 M281.8 M
Very volatile
Property Plant And Equipment Net4.1 M4.4 M34.9 M
Pretty Stable
Current Deferred Revenue90.6 K95.4 K9.5 M
Slightly volatile
Cash74.6 M78.5 M1.1 B
Slightly volatile
Non Current Assets Total30.8 M32.4 M355.6 M
Pretty Stable
Cash And Short Term Investments189.4 M199.4 M900.7 M
Pretty Stable
Net ReceivablesM1.1 M9.7 M
Pretty Stable
Common Stock Shares Outstanding77.8 M93.4 M67.3 M
Slightly volatile
Short Term Investments170 M94.6 M225.2 M
Pretty Stable
Liabilities And Stockholders Equity232.4 M244.6 M1.9 B
Pretty Stable
Non Current Liabilities Total2.6 M2.8 M979.6 M
Slightly volatile
Other Current Assets1.8 M1.9 M603.6 M
Pretty Stable
Other Stockholder Equity1.6 B1.7 BB
Slightly volatile
Total Liabilities9.8 M10.4 M1.3 B
Slightly volatile
Total Current Assets193 M203.2 M1.5 B
Pretty Stable
Intangible Assets14.2 M15 M112.4 M
Slightly volatile
Common Stock20.8 K21.9 K30.1 K
Slightly volatile
Non Currrent Assets Other1.5 M1.6 M28.2 M
Pretty Stable
Capital Lease Obligations6.7 M3.5 M14 M
Slightly volatile
Net Invested Capital316.7 M181 M585.3 M
Slightly volatile
Property Plant And Equipment Gross3.4 M3.6 M25.1 M
Slightly volatile
Capital Stock15.4 K17.1 K19.2 K
Slightly volatile
Net Working Capital301.6 M151.4 M537.4 M
Slightly volatile
Short and Long Term Debt3.8 M4.9 M3.1 M
Slightly volatile
Long Term Debt6.6 M7.5 M8.2 M
Slightly volatile

NovaBridge Biosciences Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.6 M1.7 M3.9 M
Pretty Stable
Selling General Administrative432.4 M248.9 M235.5 M
Slightly volatile
Other Operating Expenses320.9 M337.8 M582.8 M
Pretty Stable
Research Development135.9 M143 M310.9 M
Pretty Stable
Total Operating Expenses320.9 M337.8 M580 M
Pretty Stable
Net Interest Income6.9 M8.6 M4.6 M
Slightly volatile
Interest Income6.9 M8.6 M4.6 M
Slightly volatile
Reconciled Depreciation836.2 K880.2 K4.1 M
Slightly volatile

NovaBridge Biosciences Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow329.9 M347.3 M795.5 M
Slightly volatile
Other Cashflows From Financing Activities348.7 K367.1 K606.1 M
Slightly volatile
Depreciation1.1 M1.1 M9.5 M
Slightly volatile
Capital Expenditures41 K43.2 K16.1 M
Slightly volatile
End Period Cash Flow58.3 M61.4 M1.1 B
Pretty Stable
Dividends Paid4.2 M4.8 M5.2 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Dividend Yield8.0E-49.0E-40.001
Slightly volatile
Capex To Depreciation0.05360.05646.1586
Slightly volatile
Cash Per Share2.332.4619.5291
Pretty Stable
Income Quality0.741.220.7768
Pretty Stable
Intangibles To Total Assets0.0070.00730.1724
Slightly volatile
Current Ratio19.7518.817.3011
Slightly volatile
Capex Per Share6.0E-47.0E-40.2544
Slightly volatile
Average Receivables54.5 M37.8 M57.9 M
Slightly volatile
Interest Debt Per Share0.05220.0552.2451
Slightly volatile
Debt To Assets0.01990.0210.1142
Slightly volatile
Graham Number39.3544.2748.3226
Slightly volatile
Ebt Per Ebit1.370.871.3742
Slightly volatile
Quick Ratio19.7518.817.346
Slightly volatile
Net Income Per E B T0.490.511.0035
Pretty Stable
Cash Ratio4.027.273.6758
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.131.151.0616
Pretty Stable
Debt Ratio0.01990.0210.1142
Slightly volatile
Gross Profit Margin21.9820.936.9621
Slightly volatile

NovaBridge Biosciences Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap75.4 M79.4 M5.6 B
Very volatile

NovaBridge Fundamental Market Drivers

About NovaBridge Biosciences Financial Statements

NovaBridge Biosciences shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although NovaBridge Biosciences investors may analyze each financial statement separately, they are all interrelated. The changes in NovaBridge Biosciences' assets and liabilities, for example, are also reflected in the revenues and expenses on on NovaBridge Biosciences' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue95.4 K90.6 K
Stock Based Compensation To Revenue 2.63  2.76 
Sales General And Administrative To Revenue 16.38  17.20 
Research And Ddevelopement To Revenue 29.32  30.78 
Capex To Revenue 0.04  0.04 
Revenue Per Share 0.06  0.06 
Ebit Per Revenue(131.04)(124.49)

Pair Trading with NovaBridge Biosciences

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NovaBridge Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NovaBridge Biosciences will appreciate offsetting losses from the drop in the long position's value.

Moving together with NovaBridge Stock

  0.67LIPO Lipella PharmaceuticalsPairCorr

Moving against NovaBridge Stock

  0.79F Ford MotorPairCorr
  0.77DD Dupont De NemoursPairCorr
  0.74MMM 3M Company Earnings Call This WeekPairCorr
  0.73BOF BranchOut Food CommonPairCorr
  0.73ACR-PC ACRES Commercial RealtyPairCorr
The ability to find closely correlated positions to NovaBridge Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NovaBridge Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NovaBridge Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NovaBridge Biosciences to buy it.
The correlation of NovaBridge Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NovaBridge Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NovaBridge Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for NovaBridge Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for NovaBridge Stock Analysis

When running NovaBridge Biosciences' price analysis, check to measure NovaBridge Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NovaBridge Biosciences is operating at the current time. Most of NovaBridge Biosciences' value examination focuses on studying past and present price action to predict the probability of NovaBridge Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NovaBridge Biosciences' price. Additionally, you may evaluate how the addition of NovaBridge Biosciences to your portfolios can decrease your overall portfolio volatility.